Novartis: new positive data for Cosentyx
(CercleFinance.com) - Novartis announces new positive data in its Phase III Prevent trial, evaluating the efficacy and safety of Cosentyx (secukinumab) in patients with non-radiographic axial spondylitis (nr-axSpA).
The trial achieved its primary endpoint by showing, after 52 weeks, a clinically significant reduction in disease activity compared to placebo. It also demonstrated a sustained response and safety profile consistent with previous clinical trials.
This data adds to five years of clinical data supporting Cosentyx's long-term efficacy and safety in ankylosing spondylitis, psoriatic arthritis and psoriasis, Novartis said.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The trial achieved its primary endpoint by showing, after 52 weeks, a clinically significant reduction in disease activity compared to placebo. It also demonstrated a sustained response and safety profile consistent with previous clinical trials.
This data adds to five years of clinical data supporting Cosentyx's long-term efficacy and safety in ankylosing spondylitis, psoriatic arthritis and psoriasis, Novartis said.
Copyright (c) 2019 CercleFinance.com. All rights reserved.